Gary Bridger - Net Worth and Insider Trading
Gary Bridger Net Worth
The estimated net worth of Gary Bridger is at least $66,097 dollars as of 2024-11-13. Gary Bridger is the Director of Neoleukin Therapeutics Inc and owns about 18,939 shares of Neoleukin Therapeutics Inc (NLTX) stock worth over $66,097. Details can be seen in Gary Bridger's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Gary Bridger has not made any transactions after 2014-03-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Gary Bridger
Gary Bridger Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Gary Bridger owns 4 companies in total, including X4 Pharmaceuticals Inc (XFOR) , Neoleukin Therapeutics Inc (NLTX) , and Alder BioPharmaceuticals Inc (ALDR) among others .
Click here to see the complete history of Gary Bridger’s form 4 insider trades.
Insider Ownership Summary of Gary Bridger
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| XFOR | X4 Pharmaceuticals Inc | 2019-03-13 | director |
| NLTX | Neoleukin Therapeutics Inc | 2014-03-06 | director |
| ALDR | Alder BioPharmaceuticals Inc | 2015-10-31 | director |
 | | 2014-11-21 | EVP & Research & Development |
Gary Bridger Latest Holdings Summary
Gary Bridger currently owns a total of 1 stock. Gary Bridger owns 18,939 shares of Neoleukin Therapeutics Inc (NLTX) as of March 6, 2014, with a value of $66,097.
Latest Holdings of Gary Bridger
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NLTX | Neoleukin Therapeutics Inc | 2014-03-06 | 18,939 | 3.49 | 66,097 |
Holding Weightings of Gary Bridger
Gary Bridger Form 4 Trading Tracker
According to the SEC Form 4 filings, Gary Bridger has made a total of 0 transactions in Neoleukin Therapeutics Inc (NLTX) over the past 5 years. The most-recent trade in Neoleukin Therapeutics Inc is the sale of 0 shares on March 6, 2014, which brought Gary Bridger around $0.
Insider Trading History of Gary Bridger
- 1
Gary Bridger Trading Performance
Gary Bridger Ownership Network
Ownership Network List of Gary Bridger
Ownership Network Relation of Gary Bridger
Gary Bridger Owned Company Details
What does X4 Pharmaceuticals Inc do?
Who are the key executives at X4 Pharmaceuticals Inc?
Gary Bridger is the director of X4 Pharmaceuticals Inc. Other key executives at X4 Pharmaceuticals Inc include director & President and CEO Paula Ragan , Chief Scientific Officer Arthur Taveras , and Chief Operating Officer Mary Dibiase .
X4 Pharmaceuticals Inc (XFOR) Insider Trades Summary
Over the past 18 months, Gary Bridger made no insider transaction in X4 Pharmaceuticals Inc (XFOR). Other recent insider transactions involving X4 Pharmaceuticals Inc (XFOR) include a net sale of 601,883 shares made by Paula Ragan , a net sale of 161,480 shares made by Mary Dibiase , and a net sale of 552,345 shares made by Adam S. Mostafa .
In summary, during the past 3 months, insiders sold 660,362 shares of X4 Pharmaceuticals Inc (XFOR) in total and bought 0 shares, with a net sale of 660,362 shares. During the past 18 months, 1,626,785 shares of X4 Pharmaceuticals Inc (XFOR) were sold and 25,000 shares were bought by its insiders, resulting in a net sale of 1,601,785 shares.
X4 Pharmaceuticals Inc (XFOR)'s detailed insider trading history can be found in Insider Trading Tracker table.
X4 Pharmaceuticals Inc Insider Transactions
Gary Bridger Mailing Address
Above is the net worth, insider trading, and ownership report for Gary Bridger. You might contact Gary Bridger via mailing address: C/o Five Corners Capital, 700 West Georgia Street, Suite 2500, Vancouver A1 V7y 1b3.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
